Alkermes to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Alkermes (Nasdaq: ALKS) announced its participation in two upcoming investor conferences. Management will present at the Jefferies Healthcare Conference on June 6, 2024, at 1:30 p.m. EDT and at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 10:40 a.m. EDT. The presentations will be webcast live and available under the Investors tab on Alkermes' website for 14 days. Alkermes is a biopharmaceutical company with a portfolio targeting alcohol and opioid dependence, schizophrenia, and bipolar I disorder, along with a pipeline for neurological disorders.

Positive

• Alkermes' participation in prominent investor conferences may enhance visibility and attract investor interest.
• Webcasting the presentations live provides accessibility and transparency for current and potential investors.
• The company's diverse product portfolio and pipeline indicate a strong focus on treating significant neurological and psychiatric conditions.

Negative

• The announcement lacks specific new financial data or clinical trial results, potentially reducing its immediate impact on stock performance.
• No updates on revenue or profitability, which could be a concern for investors looking for financial performance indicators.

DUBLIN, May 29, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.

Jefferies Healthcare Conference
Date/Time: Thursday, June 6, 2024 at 1:30 p.m. EDT (6:30 p.m. BST)

Goldman Sachs 45^th Annual Global Healthcare Conference
Date/Time: Tuesday, June 11, 2024 at 10:40 a.m. EDT (3:40 p.m. BST)

The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-two-upcoming-investor-conferences-302158279.html

SOURCE Alkermes plc

FAQ

When will Alkermes present at the Jefferies Healthcare Conference?

Alkermes will present at the Jefferies Healthcare Conference on June 6, 2024, at 1:30 p.m. EDT.

When is Alkermes presenting at the Goldman Sachs 45th Annual Global Healthcare Conference?

Alkermes will present on June 11, 2024, at 10:40 a.m. EDT.

Where can investors access the live webcasts of Alkermes' presentations?

Investors can access the live webcasts under the Investors tab on the Alkermes website.

What is the ticker symbol for Alkermes?

The ticker symbol for Alkermes is ALKS.

What kind of products does Alkermes develop?

Alkermes develops medicines for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and neurological disorders.